CAPPED BONUSZERTIFIKAT - ABBOTT LABORATORIES Stock

Certificat

DE000PC65XH9

Real-time Bid/Ask 04:06:36 2024-05-20 am EDT
75.36 EUR / 75.94 EUR +0.23% Intraday chart for CAPPED BONUSZERTIFIKAT - ABBOTT LABORATORIES
Current month-0.61%
1 month-1.17%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-20 75.35 -0.17%
24-05-17 75.48 +0.17%
24-05-16 75.35 -0.15%
24-05-15 75.46 -0.46%
24-05-14 75.81 -0.03%

Delayed Quote Börse Stuttgart

Last update May 20, 2024 at 03:44 am EDT

More quotes

Static data

Product typeBonus- and Part-Guarantee-Certificates
Buy / SellCALL
Underlying ABBOTT LABORATORIES
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PC65XH
ISINDE000PC65XH9
Date issued 2024-03-25
Strike 90 $
Maturity 2025-12-19 (579 Days)
Parity 1 : 1
Emission price 72.58
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 76.39
Lowest since issue 75.16
Spread 0.6
Spread %0.79%

Company Profile

Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
Sector
-
More about the company

Ratings for Abbott Laboratories

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Abbott Laboratories

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
104.1 USD
Average target price
126.1 USD
Spread / Average Target
+21.19%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW